SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Harry D. Kramer who wrote (1252)12/22/1997 7:15:00 AM
From: WWS  Respond to of 2205
 
Harry, adding to the recent sector weakness was rejection last week of several biotech NDA's by FDA. Most notable was the case of DepoTech, and to read the thread (starting at URL below) is a case study of how companies can easily fool themselves and their investors by not understanding (or ignoring) the stringent statistical requirements expected of Phase III trials.
Message 3003392



To: Harry D. Kramer who wrote (1252)12/23/1997 8:51:00 PM
From: Marshall Teitelbaum  Read Replies (1) | Respond to of 2205
 
Harry, Bill, and all others,

Have a great holiday and lots of good wishes for the new year.

BTW, Harry, looks like our recent discussion about finishing options expirations and getting past year-end tax selling may yet hold some merit, although the biotech sector may also have generally bottomed out, in general, unless the market gets hit particularly hard. Good luck here and to all.

Best to all,

Marshall


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News